Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
Sklavenitis-Pistofidis R, Aranha MP, Redd RA, Baginska J, Haradhvala NJ, Hallisey M, Dutta AK, Savell A, Varmeh S, Heilpern-Mallory D, Ujwary S, Zavidij O, Aguet F, Su NK, Lightbody ED, Bustoros M, Tahri S, Mouhieddine TH, Wu T, Flechon L, Anand S, Rosenblatt JM, Zonder J, Vredenburgh JJ, Boruchov A, Bhutani M, Usmani SZ, Matous J, Yee AJ, Jakubowiak A, Laubach J, Manier S, Nadeem O, Richardson P, Badros AZ, Mateos MV, Trippa L, Getz G, Ghobrial IM. Sklavenitis-Pistofidis R, et al. Among authors: richardson p. Cancer Cell. 2022 Nov 14;40(11):1358-1373.e8. doi: 10.1016/j.ccell.2022.10.017. Cancer Cell. 2022. PMID: 36379208 Free PMC article.
Proteasome inhibitor therapy in multiple myeloma.
Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC. Chauhan D, et al. Among authors: richardson p. Mol Cancer Ther. 2005 Apr;4(4):686-92. doi: 10.1158/1535-7163.MCT-04-0338. Mol Cancer Ther. 2005. PMID: 15827343 Review.
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P, Schlossman R, Ghobrial I, Raje N, Munshi N, Anderson KC. Chauhan D, et al. Among authors: richardson p. Oncogene. 2007 Apr 5;26(16):2374-80. doi: 10.1038/sj.onc.1210028. Epub 2006 Oct 2. Oncogene. 2007. PMID: 17016430
Emerging drugs in multiple myeloma.
Ghobrial IM, Leleu X, Hatjiharissi E, Hideshima T, Mitsiades C, Schlossman R, Anderson KC, Richardson P. Ghobrial IM, et al. Among authors: richardson p. Expert Opin Emerg Drugs. 2007 Mar;12(1):155-63. doi: 10.1517/14728214.12.1.155. Expert Opin Emerg Drugs. 2007. PMID: 17355220 Review.
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial IM, Anderson KC. Tai YT, et al. Among authors: richardson p. Blood. 2007 Sep 1;110(5):1656-63. doi: 10.1182/blood-2007-03-081240. Epub 2007 May 17. Blood. 2007. PMID: 17510321 Free PMC article. Clinical Trial.
Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.
Younes H, Leleu X, Hatjiharissi E, Moreau AS, Hideshima T, Richardson P, Anderson KC, Ghobrial IM. Younes H, et al. Among authors: richardson p. Clin Cancer Res. 2007 Jul 1;13(13):3771-5. doi: 10.1158/1078-0432.CCR-06-2921. Clin Cancer Res. 2007. PMID: 17606706 Review.
Novel therapeutic avenues in myeloma: changing the treatment paradigm.
Ghobrial J, Ghobrial IM, Mitsiades C, Leleu X, Hatjiharissi E, Moreau AS, Roccaro A, Schlossman R, Hideshima T, Anderson KC, Richardson P. Ghobrial J, et al. Among authors: richardson p. Oncology (Williston Park). 2007 Jun;21(7):785-92; discussion 798-800. Oncology (Williston Park). 2007. PMID: 17722741 Free article. Review.
The treatment of relapsed and refractory multiple myeloma.
Richardson P, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Chauhan D, Munshi N, Anderson K. Richardson P, et al. Hematology Am Soc Hematol Educ Program. 2007:317-23. doi: 10.1182/asheducation-2007.1.317. Hematology Am Soc Hematol Educ Program. 2007. PMID: 18024646 Review.
Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.
Huston A, Leleu X, Jia X, Moreau AS, Ngo HT, Runnels J, Anderson J, Alsayed Y, Roccaro A, Vallet S, Hatjiharissi E, Tai YT, Sportelli P, Munshi N, Richardson P, Hideshima T, Roodman DG, Anderson KC, Ghobrial IM. Huston A, et al. Among authors: richardson p. Clin Cancer Res. 2008 Feb 1;14(3):865-74. doi: 10.1158/1078-0432.CCR-07-1299. Clin Cancer Res. 2008. PMID: 18245550
2,363 results